299. 嚢胞性線維症
[臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002677-38-BE
(EUCTR)
11/05/201603/03/2016An investigation of the effect of CTX-4430 on lung inflammation in patients with cystic fibrosisA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis - EMPIRE CF Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: CTX-4430
Product Code: CTX-4430
INN or Proposed INN: acebilustat
Other descriptive name: CRC3357, ZK-355322, Leukoton
Product Name: CTX-4430
Product Code: CTX-4430
INN or Proposed INN: acebilustat
Other descriptive name: CRC3357, ZK-355322, Leukoton
Celtaxsys Inc.NULLNot RecruitingFemale: yes
Male: yes
195Phase 2France;United States;Canada;Belgium;Germany;Italy;United Kingdom
2EUCTR2015-002677-38-DE
(EUCTR)
09/05/201603/11/2015An investigation of the effect of CTX-4430 on lung inflammation in patients with cystic fibrosisA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis - EMPIRE CF Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: CTX-4430
Product Code: CTX-4430
INN or Proposed INN: acebilustat
Other descriptive name: CRC3357, ZK-355322, Leukoton
Product Name: CTX-4430
Product Code: CTX-4430
INN or Proposed INN: acebilustat
Other descriptive name: CRC3357, ZK-355322, Leukoton
Celtaxsys Inc.NULLNot RecruitingFemale: yes
Male: yes
195Phase 2France;United States;Canada;Belgium;Germany;Italy;United Kingdom
3EUCTR2015-002677-38-IT
(EUCTR)
06/04/201625/11/2015An investigation of the effect of CTX-4430 on lung inflammation in patients with cystic fibrosisA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis - EMPIRE CF Cystic Fibrosis
MedDRA version: 18.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 18.1;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: CTX-4430
Product Code: CTX-4430
INN or Proposed INN: acebilustat
Other descriptive name: CRC3357, ZK-355322, Leukoton
Product Name: CTX-4430
Product Code: CTX-4430
INN or Proposed INN: acebilustat
Other descriptive name: CRC3357, ZK-355322, Leukoton
Celtaxsys Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
195Phase 2France;United States;Belgium;Netherlands;Germany;United Kingdom;Italy
4EUCTR2015-002677-38-GB
(EUCTR)
04/02/201627/10/2015An investigation of the effect of CTX-4430 on lung inflammation in patients with cystic fibrosisA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis - EMPIRE CF Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Celtaxsys Inc.NULLNot Recruiting Female: yes
Male: yes
195Phase 2France;United States;Canada;Belgium;Germany;Italy;United Kingdom
5NCT02443688
(ClinicalTrials.gov)
October 30, 20158/5/2015EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) PatientsA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic FibrosisCystic FibrosisDrug: CTX-4430;Drug: PlaceboCeltaxsys, Inc.NULLCompleted18 Years30 YearsAll200Phase 2United States;Belgium;Canada;France;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01944735
(ClinicalTrials.gov)
September 20136/9/2013Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis PatientsA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen DaysCystic FibrosisDrug: CTX-4430;Drug: PlaceboCeltaxsys, Inc.CelerionCompleted18 Years55 YearsBoth17Phase 1United Kingdom